Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies

American Journal of Transplantation

Volumn 3, Issue 5, 2003, Pages 534-542

  Shaw, Leslie M ^a   Korecka, Magdalena ^a   Venkataramanan, Raman ^b   Goldberg, Lee ^c   Bloom, Roy ^c   Brayman, Kenneth L ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Mycophenolic acid; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ALBUMIN; CYCLOSPORIN A; FERROUS SULFATE; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

CATALYSIS; CELL IMMORTALIZATION; CELL PROLIFERATION; DIARRHEA; DRUG EFFECT; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY GRAFT REJECTION; LYMPHOCYTE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INHIBITION; NONHUMAN; PATIENT; PHARMACODYNAMICS; PLASMA; REVIEW; TREATMENT OUTCOME;

ADULT; CATALYSIS; CHILD; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MODELS, CHEMICAL; MYCOPHENOLIC ACID; SERUM ALBUMIN; TIME FACTORS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0038246498     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00079.x     Document Type: Review

References (57)

1. Gummert JF, Barten MJ, Sherwood SW et al. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte: proliferation and activation correlates with pharmacokinetics. J Pharm Exp Ther 1999; 291: 1100-1112.
2. Gummert JF, Barten MJ, van Gelder T et al. Pharmacodynamics of mycophenolic acid in heart transplant recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Transplantation 2000; 70: 1038-1048.
3. Barten MJ, van Gelder T, Gummert JF et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002; 2: 719-732.
4. Lui SL, Ramassar V, Urmson J, Halloran PF. Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion. Transplant Immunol 1998; 6: 23-32.
5. Cohn RG, Mirkovich A, Dunlap B et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999; 68: 411-418.
6. Quemeneur L, Flacher M, Gerland L-M et al. Mycophenolic acid inhibits IL-2 dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002; 169: 2747-2755.
7. Wu JC. Mycophenolate mofetil molecular mechanisms of action. Perspect Drug Discovery Design 1994; 2: 185-204.
8. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47: 215-245.
9. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996; 62: 666-672.
10. Sanguer S, Breil M, Baron C, Dahamane D, Asrier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999; 65: 640-648.
11. Millan O, Oppenheimer F, Brunet M et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 2000; 46: 1376-1378.
12. Budde K, Glander P, Bauer S et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000; 38: 1213-1216.
13. Albrecht W, Storck M, Pfetsch E, Martin W, Abendroth D. Development and application of a high performance liquid chromatography-based assay for determination of the activity of inosine monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit 2000; 22: 283-294.
14. Budde K, Braun K-P, Glander P et al. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. Transplant Proc 2002; 34: 1748-50.
15. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455.
16. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998; 38: 268-275.
17. Shaw LM, Korecka M, Aradhye S et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000; 40: 624-633.
18. Weber LT, Shipkova M, Lamersdorf T et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998; 9: 1511-1520.
19. Oellerich M, Shipkova M, Schutz E et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric renal transplant recipients: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 2000; 22: 20-26.
20. Meiser BM, Pfeiffer M, Schmidt D et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143-149.
21. DeNofrio D, Loh E, Kao A et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000; 19: 1071-1076.
22. Jain A, Venkataramanan R, Hamad IS et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharm 2001; 41: 268-276.
23. Bornhauser M, Schuler U, Porksen G et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499-504.
24. Kiehl MG, Shipkova M, Basara N et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem 2000; 33: 203-208.
25. Jenke A, Renner U, Richte M et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplantation 2001; 15: 176-184.
26. Korecka M, Nikolic D, van Breemen RB, Shaw LM. The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. Clin Chem 1999; 45: 1047-1050.
27. Shipkova M, Armstrong VW, Wieland E et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999; 126: 1075-1082.
28. Sintchak MD, Fleming MA, Futer O et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921-930.
29. Wieland E, Shipkova M, Schellhas U et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000; 33: 107-113.
30. Bullingham R, Shah J, Goldblum R, Shciff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis. Br J Clin Pharmacol 1996; 41: 513-516.
31. Morii M, Ueno K, Ogawa A et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharm Ther 2000; 68: 613-616.
32. Fisher MB, Paine MF, Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metabolism Rev 2001; 33 (3-4): 273-297.
33. Soldin SJ, Steele BW. Mini-review: therapeutic drug monitoring in pediatrics. Clin Biochem 2000; 33: 333-335.
34. Dipchand AI, Pietra B, McCrindle BW, Rosebrook-Bicknell HL, Boucek MM. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant 2001; 20: 1035-1043.
35. Smak Gregoor PJH, de Sevaux RG, Hene RJ et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68: 1603-1606.
36. Smak Gregoor PJ, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14: 706-708.
37. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatric Nephrol 2000; 14: 100-104.
38. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119-128.
39. Zucker K, Tsaroucha A, Olson L et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999; 21: 35-43.
40. Holt DW, Ostraat O, Grinyo JM et al. Mycophenolate mofetil may be given at lower doses when used in association with sirolimus in renal transplant patients. [abstract]. Am J Transplant 2001; 1 (Suppl. 1): 247.
41. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995; 41: 1011-1017.
42. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001; 34: 17-22.
43. Kaplan B, Meier-Kriesche HU, Friedman G et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Phamracol 1999; 39: 715-720.
44. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 2000; 22: 27-30.
45. Weber LT, Shipkova M, Armstrong VW et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13: 759-768.
46. Takahashi K, Ochaii T, Uchida K et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc 1995; 27: 1421-1424,
47. van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266.
48. Pillans PI, Rigby RJ, Kubler P et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem 2001; 34: 77-81.
49. Mourad M, Malaise J, Eddour DC et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 88-94.
50. Mourad M, Malaise J, Eddour DC et al. Pharmacokinetic basis for the efficient and sale use of low dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001; 47: 1241-1248.
51. Weber LT, Shipkova M, Armstrong VW, Wagner N et al. Comparison of the EMIT immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002; 48: 517-525.
52. Meiser BM, Pfeiffer M, Schmidt D et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143-149.
53. Yamani MH, Starling RC, Goormastic M et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000; 69: 2326-2330.
54. Nicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998; 31: 329-333.
55. Hale MD, Nicholls AJ, Bullingham RES. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672-683.
56. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-315.
57. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497-1504.